VERA · Vera Therapeutics, Inc.
$37.17
+0.18 (+0.49%)
At close · Jul 21
Market Cap
$2.67B
Shares
71.78M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$299.62M
-96.9%
FY2025
Diluted EPS
-$4.66
-69.5%
FY2025
Operating Cash Flow
-$241.1M
-79%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $259.99M | $215.26M | $126.17M | $78.23M | $68.99M | $22.48M | |
| $123.42M | $100.22M | $41M | $23.79M | $21.91M | $11.92M | |
| — | $468K | $105K | -$4.09M | -$846K | $176K | |
| — | — | — | — | — | $0 | |
| $383.41M | $315.47M | $167.17M | $102.01M | $90.9M | $34.4M | |
| -$383.41M | -$315.47M | -$167.17M | -$102.01M | -$90.9M | -$34.4M | |
| $7.56M | $7.53M | $7.63M | $3.79M | $992K | $20K | |
| $23.93M | $24.48M | $20.71M | $7.98M | $1.75M | $15K | |
| $14.46M | $15.86M | $15.02M | $6.02M | $1.85M | $1.79M | |
| — | -$299.61M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | |
| — | $1000 | $1000 | $1000 | $1000 | -$1000 | |
| -$368.95M | -$299.62M | -$152.15M | -$95.99M | -$89.06M | -$32.61M | |
| USD/shares | — | -$4.66 | -$2.75 | -$2.25 | -$3.35 | — |
| USD/shares | — | -$4.66 | -$2.75 | -$2.25 | -$3.35 | — |
| shares | — | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M |
| shares | — | 64.23M | 55.33M | 42.71M | 26.57M | 13.44M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2024–FY2025: $13K in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.68×
EV/EBIT
—
Biotechnology median 26.45×
P/E (TTM)
—
Biotechnology median 7.21×
Key facts
CIK
1831828
CUSIP
92337R101
13F (30d)
15 filings
15 filers
Visit website
Investor relations